^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Neurofibrosarcoma |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A high-throughput screening platform identifies novel combination treatments for Malignant Peripheral Nerve Sheath Tumors
Published date:
05/05/2022
Excerpt:
One of the combinations, MK-1775 with Doxorubicin, significantly reduced tumor growth in a sporadic PDOX model (MPNST-SP-01) (sevenfold) and in an NF1-PDOX model (MPNST-NF1-09) (fourfold) and presented greater effects in TP53 mutated MPNST cell lines.
Secondary therapy:
doxorubicin hydrochloride
DOI:
10.1158/1535-7163.MCT-21-0947
